Visual abstract | Belantamab mafodotin in combination with Pd for RRMM: Latest data from DREAMM-8

The Multiple Myeloma Hub presents a visual abstract of the phase III DREAMM-8 study (NCT04484623), which evaluated the combination of belantamab mafodotin, pomalidomide, and dexamethasone (BPd) vs the combination of pomalidomide, bortezomib, and dexamethasone (PVd) for the treatment of patients with relapsed/refractory multiple myeloma (RRMM). The DREAMM-8 study also evaluated the impact of dose modifications and extended treatment intervals on toxicity, efficacy, and quality of life.

 Key takeaways:

• The BPd combination resulted in a significantly reduced risk of disease progression or death compared with PVd for patients with RRMM, at a hazard ratio of 0.52 (95% CI, 0.37–0.73 [p < 0.001]).
• There were higher rates of complete response (CR) and an increased duration of response observed with BPd, as well as a higher ≥CR/measurable residual disease rate.
• While ocular side effects were common with BPd, they were largely manageable with dose modifications, without sacrificing efficacy outcomes.
• BPd provides a promising option for the treatment of RRMM in the community setting, as well as in areas without access to other targeted therapies, such as bispecific antibodies and chimeric antigen receptor T-cell therapies.

 

This educational resource is independently supported by GSK. All content was developed by SES in collaboration with an expert steering committee; funders were allowed no influence on the content of this resource.